{"id":"https://openalex.org/W4281715218","doi":"https://doi.org/10.1200/jco.2022.40.16_suppl.2560","title":"Dose escalation of davoceticept, a conditional CD28 costimulator and dual checkpoint inhibitor, in advanced malignancies (NEON-1).","display_name":"Dose escalation of davoceticept, a conditional CD28 costimulator and dual checkpoint inhibitor, in advanced malignancies (NEON-1).","publication_year":2022,"publication_date":"2022-06-01","ids":{"openalex":"https://openalex.org/W4281715218","doi":"https://doi.org/10.1200/jco.2022.40.16_suppl.2560"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2022.40.16_suppl.2560","doi":"https://doi.org/10.1200/jco.2022.40.16_suppl.2560","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2022.40.16_suppl.2560","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5030169825","display_name":"Diwakar Davar","orcid":"https://orcid.org/0000-0002-7846-8055","observed_orcids":["https://orcid.org/0000-0002-7846-8055"]},"institutions":[{"id":"https://openalex.org/I4210128526","display_name":"UPMC Hillman Cancer Center","ror":"https://ror.org/03bw34a45","country_code":"US","type":"facility","lineage":["https://openalex.org/I170201317","https://openalex.org/I4210128526"]},{"id":"https://openalex.org/I4210134769","display_name":"University of Pittsburgh Medical Center","ror":"https://ror.org/04ehecz88","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210098814","https://openalex.org/I4210134769"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Diwakar Davar","raw_affiliation_strings":["University of Pittsburgh Medical Center, Hillman Cancer Center, Pittsburgh, PA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Pittsburgh Medical Center, Hillman Cancer Center, Pittsburgh, PA;","institution_ids":["https://openalex.org/I4210128526","https://openalex.org/I4210134769"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5082674870","display_name":"Justin C. Moser","orcid":"https://orcid.org/0000-0002-0643-6759","observed_orcids":["https://orcid.org/0000-0002-0643-6759"]},"institutions":[{"id":"https://openalex.org/I4210130412","display_name":"HonorHealth","ror":"https://ror.org/03szbwj17","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210130412"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Justin C Moser","raw_affiliation_strings":["HonorHealth Research and Innovation Institute, Scottsdale, AZ;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"HonorHealth Research and Innovation Institute, Scottsdale, AZ;","institution_ids":["https://openalex.org/I4210130412"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5079833339","display_name":"Michael Millward","orcid":"https://orcid.org/0000-0002-1744-1617","observed_orcids":["https://orcid.org/0000-0002-1744-1617"]},"institutions":[{"id":"https://openalex.org/I177877127","display_name":"The University of Western Australia","ror":"https://ror.org/047272k79","country_code":"AU","type":"education","lineage":["https://openalex.org/I177877127"]},{"id":"https://openalex.org/I4210156497","display_name":"Linear Clinical Research","ror":"https://ror.org/05vnpr825","country_code":"AU","type":"facility","lineage":["https://openalex.org/I4210156497"]}],"countries":["AU"],"is_corresponding":false,"raw_author_name":"Michael Millward","raw_affiliation_strings":["Linear Clinical Research & University of Western Australia, Nedlands, Australia;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Linear Clinical Research & University of Western Australia, Nedlands, Australia;","institution_ids":["https://openalex.org/I177877127","https://openalex.org/I4210156497"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5002781091","display_name":"Mark Voskoboynik","orcid":"https://orcid.org/0000-0002-4242-1300","observed_orcids":["https://orcid.org/0000-0002-4242-1300"]},"institutions":[{"id":"https://openalex.org/I2801993434","display_name":"The Alfred Hospital","ror":"https://ror.org/01wddqe20","country_code":"AU","type":"healthcare","lineage":["https://openalex.org/I2801993434","https://openalex.org/I4210163178"]},{"id":"https://openalex.org/I56590836","display_name":"Monash University","ror":"https://ror.org/02bfwt286","country_code":"AU","type":"education","lineage":["https://openalex.org/I56590836"]}],"countries":["AU"],"is_corresponding":false,"raw_author_name":"Mark Voskoboynik","raw_affiliation_strings":["The Alfred Hospital and Monash University, Melbourne, Australia;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Alfred Hospital and Monash University, Melbourne, Australia;","institution_ids":["https://openalex.org/I2801993434","https://openalex.org/I56590836"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5003770647","display_name":"Nehal J. Lakhani","orcid":"https://orcid.org/0009-0005-6327-0176","observed_orcids":["https://orcid.org/0009-0005-6327-0176"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Nehal J. Lakhani","raw_affiliation_strings":["START Midwest, Grand Rapids, MI;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"START Midwest, Grand Rapids, MI;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005462156","display_name":"Rachel E. Sanborn","orcid":"https://orcid.org/0000-0003-0542-6054","observed_orcids":["https://orcid.org/0000-0003-0542-6054"]},"institutions":[{"id":"https://openalex.org/I2801670537","display_name":"Providence Portland Medical Center","ror":"https://ror.org/015tmw922","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2801670537","https://openalex.org/I4210160466","https://openalex.org/I94396219"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Rachel E. Sanborn","raw_affiliation_strings":["Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR;","institution_ids":["https://openalex.org/I2801670537"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5076779423","display_name":"Jaspreet Singh Grewal","orcid":"https://orcid.org/0000-0002-2219-7655","observed_orcids":["https://orcid.org/0000-0002-2219-7655"]},"institutions":[{"id":"https://openalex.org/I202709704","display_name":"Norton Healthcare","ror":"https://ror.org/0266h1q26","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I202709704"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jaspreet Singh Grewal","raw_affiliation_strings":["Norton Cancer Institute, Louisville, KY;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Norton Cancer Institute, Louisville, KY;","institution_ids":["https://openalex.org/I202709704"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5038051144","display_name":"Ajita Narayan","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ajita Narayan","raw_affiliation_strings":["Horizon Medcl Grp, Lafayette, IN;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Horizon Medcl Grp, Lafayette, IN;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5007198397","display_name":"Mario Sznol","orcid":"https://orcid.org/0000-0003-4137-9662","observed_orcids":["https://orcid.org/0000-0003-4137-9662"]},"institutions":[{"id":"https://openalex.org/I1323778983","display_name":"Yale New Haven Hospital","ror":"https://ror.org/05tszed37","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1323778983","https://openalex.org/I4210117499"]},{"id":"https://openalex.org/I2802730090","display_name":"Yale Cancer Center","ror":"https://ror.org/03j7sze86","country_code":"US","type":"facility","lineage":["https://openalex.org/I2802730090","https://openalex.org/I4210117499","https://openalex.org/I4210165192"]},{"id":"https://openalex.org/I32971472","display_name":"Yale University","ror":"https://ror.org/03v76x132","country_code":"US","type":"education","lineage":["https://openalex.org/I32971472"]},{"id":"https://openalex.org/I4210165192","display_name":"Smilow Cancer Hospital","ror":"https://ror.org/05q3szf80","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210117499","https://openalex.org/I4210165192"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mario Sznol","raw_affiliation_strings":["Yale Cancer Center, Smilow Cancer Hospital of the Yale\u2013New Haven Hospital, Yale University School of Medicine, New Haven, CT;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Yale Cancer Center, Smilow Cancer Hospital of the Yale\u2013New Haven Hospital, Yale University School of Medicine, New Haven, CT;","institution_ids":["https://openalex.org/I1323778983","https://openalex.org/I2802730090","https://openalex.org/I32971472","https://openalex.org/I4210165192"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5035788052","display_name":"Stacey R. Dillon","orcid":"https://orcid.org/0000-0001-8758-3795","observed_orcids":["https://orcid.org/0000-0001-8758-3795"]},"institutions":[{"id":"https://openalex.org/I4210087354","display_name":"Alpine Immune Sciences (United States)","ror":"https://ror.org/004sp0722","country_code":"US","type":"company","lineage":["https://openalex.org/I4210087354"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Stacey R. Dillon","raw_affiliation_strings":["Alpine Immune Sciences, Seattle, WA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Alpine Immune Sciences, Seattle, WA;","institution_ids":["https://openalex.org/I4210087354"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5084947676","display_name":"Keren Schieber","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210087354","display_name":"Alpine Immune Sciences (United States)","ror":"https://ror.org/004sp0722","country_code":"US","type":"company","lineage":["https://openalex.org/I4210087354"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Keren Schieber","raw_affiliation_strings":["Alpine Immune Sciences, Inc., Seattle, WA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Alpine Immune Sciences, Inc., Seattle, WA;","institution_ids":["https://openalex.org/I4210087354"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Hany Zayed","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210087354","display_name":"Alpine Immune Sciences (United States)","ror":"https://ror.org/004sp0722","country_code":"US","type":"company","lineage":["https://openalex.org/I4210087354"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Hany Zayed","raw_affiliation_strings":["Alpine Immune Sciences, Inc., Seattle, WA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Alpine Immune Sciences, Inc., Seattle, WA;","institution_ids":["https://openalex.org/I4210087354"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108812058","display_name":"Christine Marie Dela Cruz","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Christine Marie Dela Cruz","raw_affiliation_strings":["Bristol-Myers Squibb Co, Parkway Parade, NJ, Singapore;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol-Myers Squibb Co, Parkway Parade, NJ, Singapore;","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5003855004","display_name":"Graciela Noemi Perez","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I920293368","display_name":"PRA Health Sciences","ror":"https://ror.org/02k5t6c64","country_code":"US","type":"facility","lineage":["https://openalex.org/I920293368"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Graciela Noemi Perez","raw_affiliation_strings":["PRA Health Sciences, San Diego, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"PRA Health Sciences, San Diego, CA;","institution_ids":["https://openalex.org/I920293368"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5064537078","display_name":"Stanford L. Peng","orcid":"https://orcid.org/0000-0001-7445-2542","observed_orcids":["https://orcid.org/0000-0001-7445-2542"]},"institutions":[{"id":"https://openalex.org/I4210087354","display_name":"Alpine Immune Sciences (United States)","ror":"https://ror.org/004sp0722","country_code":"US","type":"company","lineage":["https://openalex.org/I4210087354"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Stanford L. Peng","raw_affiliation_strings":["Alpine Immune Sciences, Inc., Seattle, WA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Alpine Immune Sciences, Inc., Seattle, WA;","institution_ids":["https://openalex.org/I4210087354"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":16,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":2,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"40","issue":"16_suppl","first_page":"2560","last_page":"2560"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10031","display_name":"T-cell and B-cell Immunology","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/cd28-costimulation","display_name":"CD28 costimulation","score":0.9520000219345093},{"id":"https://openalex.org/keywords/pd-l1","display_name":"PD-L1","score":0.6729999780654907},{"id":"https://openalex.org/keywords/ctla-4","display_name":"CTLA-4","score":0.9869999885559082},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitors","display_name":"immune checkpoint inhibitors","score":0.746999979019165},{"id":"https://openalex.org/keywords/t-cell-costimulation","display_name":"T cell costimulation","score":0.6480000019073486},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.6769999861717224},{"id":"https://openalex.org/keywords/advanced-solid-tumors","display_name":"advanced solid tumors","score":0.7789999842643738},{"id":"https://openalex.org/keywords/lymphoma","display_name":"lymphoma","score":0.9430000185966492},{"id":"https://openalex.org/keywords/immune-related-adverse-events","display_name":"immune-related adverse events","score":0.9350000023841858},{"id":"https://openalex.org/keywords/drug-safety-and-tolerability","display_name":"drug safety and tolerability","score":0.652999997138977},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.8709999918937683},{"id":"https://openalex.org/keywords/tumor-immune-microenvironment","display_name":"tumor immune microenvironment","score":0.421999990940094},{"id":"https://openalex.org/keywords/colorectal-cancer","display_name":"colorectal cancer","score":0.593999981880188},{"id":"https://openalex.org/keywords/pancreatic-cancer","display_name":"pancreatic cancer","score":0.9660000205039978},{"id":"https://openalex.org/keywords/renal-cell-carcinoma","display_name":"renal cell carcinoma","score":0.796999990940094}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8794571161270142},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.5958768129348755},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.49758246541023254},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.4790676534175873},{"id":"https://openalex.org/C2780057760","wikidata":"https://www.wikidata.org/wiki/Q13896859","display_name":"Pembrolizumab","level":4,"score":0.45843276381492615},{"id":"https://openalex.org/C111113717","wikidata":"https://www.wikidata.org/wiki/Q725307","display_name":"Pharmacodynamics","level":3,"score":0.42865726351737976},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.3698212504386902},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.33605140447616577},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.27681174874305725},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.26815614104270935},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.19497960805892944}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.1200/jco.2022.40.16_suppl.2560","doi":"https://doi.org/10.1200/jco.2022.40.16_suppl.2560","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2022.40.16_suppl.2560","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},{"id":"pmh:oai:pure.atira.dk:publications/a5222e3b-99ae-48ae-bb59-7d22088f8a25","doi":null,"is_oa":false,"landing_page_url":"https://www.webofscience.com/wos/woscc/full-record/WOS:000863680300783","pdf_url":null,"source":{"id":"https://openalex.org/S4306402523","display_name":"UWA Profiles and Research Repository (University of Western Australia)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I177877127","host_organization_name":"The University of Western Australia","host_organization_lineage":["https://openalex.org/I177877127"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Davar, D, Moser, J C, Millward, M, Voskoboynik, M, Lakhani, N J, Sanborn, R E, Grewal, J S, Narayan, A, Sznol, M, Dillon, S R, Schieber, K, Zayed, H, Dela Cruz, C M, Perez, G N & Peng, S L 2022, 'Dose escalation of davoceticept, a conditional CD28 costimulator and dual checkpoint inhibitor, in advanced malignancies (NEON-1)', Journal of Clinical Oncology, vol. 40, no. 16.","raw_type":"info:eu-repo/semantics/conferenceObject"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4282966676","https://openalex.org/W4401283543","https://openalex.org/W4286296475","https://openalex.org/W4308383771","https://openalex.org/W3167701545","https://openalex.org/W3083334067","https://openalex.org/W3181248287","https://openalex.org/W4399327438","https://openalex.org/W4399325171","https://openalex.org/W3211543572"],"abstract_inverted_index":{"2560":[0],"Background:":[1],"Strong":[2],"preclinical":[3,71],"rationale":[4,390],"supports":[5],"combining":[6,368],"checkpoint":[7,30,372],"inhibition":[8,373],"(CPI)":[9],"with":[10,87,95,173,328,345,371,408],"T":[11,20,304,320,325],"cell":[12,21,305],"costimulatory":[13,22],"agonists,":[14],"particularly":[15],"of":[16,29,83,151,168,209,219,303,339,348,367,380],"CD28,":[17,306],"a":[18,26,35,355,405],"critical":[19],"molecule":[23],"recognized":[24],"as":[25],"key":[27],"target":[28,199],"inhibition.":[31],"Davoceticept":[32,332],"(ALPN-202)":[33],"is":[34,75],"variant":[36],"CD80":[37],"vIgD-Fc":[38],"fusion":[39],"that":[40],"mediates":[41],"PD-L1-dependent":[42],"CD28":[43,329,341,369],"costimulation":[44,342],"and":[45,49,65,80,120,125,129,181,198,213,251,284,307,317,322,350,374,387,399,404],"inhibits":[46],"the":[47,147,152,163,210,220],"PD-L1":[48],"CTLA-4":[50],"checkpoints.":[51],"It":[52,194],"has":[53,410],"demonstrated":[54,195,269,310],"superiority":[55],"to":[56,98],"CPI-only":[57],"therapies":[58,100],"in":[59,63,66,85,159,205,248,264,343,354],"multiple":[60],"tumor":[61,359],"models":[62],"vitro":[64],"vivo,":[67,344],"while":[68],"demonstrating":[69],"favorable":[70],"safety.":[72],"Methods:":[73],"This":[74],"an":[76,287,364],"open-label":[77],"dose":[78,117,160,378],"escalation":[79,114],"expansion":[81],"study":[82,407],"davoceticept":[84,184,381],"adults":[86,172],"advanced":[88,175],"solid":[89,141,176],"tumors":[90],"or":[91,103,108],"lymphoma":[92],"(NCT04186637).":[93],"Patients":[94],"cancers":[96,104],"refractory":[97],"standard":[99,107],"including":[101,162,396],"CPIs,":[102],"without":[105],"available":[106],"curative":[109],"therapy":[110],"are":[111,135,402],"eligible.":[112],"Dose":[113],"studied":[115],"two":[116],"schedules,":[118],"Q1W":[119,153],"Q3W.":[121,193,238],"Objectives":[122],"include":[123],"safety":[124],"tolerability,":[126],"PK,":[127],"PD":[128],"preliminary":[130],"anticancer":[131],"activity.":[132],"Disease":[133],"assessments":[134],"evaluated":[136],"by":[137],"RECIST":[138],"v1.1":[139],"for":[140,280,382,391],"tumors.":[142],"A":[143],"prior":[144],"presentation":[145,156],"discussed":[146],"first":[148,257],"5":[149],"cohorts":[150],"schedule;":[154],"this":[155],"updates":[157],"progress":[158],"escalation,":[161],"Q3W":[164],"schedule.":[165],"Results:":[166],"As":[167],"January":[169],"2022,":[170],"57":[171],"various":[174],"tumors,":[177],"most":[178],"commonly":[179],"colorectal":[180],"pancreatic,":[182],"received":[183],"monotherapy,":[185],"which":[186],"was":[187,233,262,333],"well":[188,334],"tolerated":[189,335],"through":[190],"10":[191],"mg/kg":[192,237],"dose-dependent":[196],"PK":[197],"saturation.":[200],"Immune-related":[201],"AEs":[202],"(irAEs),":[203],"occurred":[204],"20/57":[206],"(35%),":[207],"mostly":[208],"skin,":[211],"endocrine":[212],"gastrointestinal":[214],"systems.":[215],"All":[216],"but":[217],"4":[218],"irAE":[221],"were":[222,246],"grade":[223,231],"1-2.":[224],"Only":[225],"one":[226],"DLT":[227],"(chronic":[228],"active":[229,377],"gastritis":[230],"3)":[232],"observed":[234,247,263],"at":[235,256,259,290,336],"3":[236],"Among":[239],"48":[240],"evaluable":[241],"patients,":[242],"unconfirmed":[243],"partial":[244],"responses":[245],"2":[249,277],"(colorectal":[250],"renal":[252],"cell).":[253],"Stable":[254],"disease,":[255],"scan":[258],"6":[260,282],"weeks,":[261],"23":[265],"(48%);":[266],"11":[267],"(23%)":[268],"volume":[270],"reduction":[271],"(target":[272],"lesion":[273],"\u0394SLD":[274],"<":[275],"0%);":[276],"had":[278,286],"SD":[279,289],">":[281],"months,":[283],"1":[285],"ongoing":[288],"8":[291],"months.":[292],"At":[293],"doses":[294,337],"above":[295],"0.1":[296],"mg/kg,":[297],"ex":[298],"vivo":[299],"analyses":[300],"showed":[301],"agonism":[302,370],"flow":[308],"cytometry":[309],"increased":[311],"circulating":[312],"activated":[313],"(ICOS+),":[314],"proliferating":[315],"(Ki-67+)":[316],"central":[318],"memory":[319],"cells,":[321,326],"reduced":[323],"regulatory":[324],"consistent":[327],"engagement.":[330],"Conclusions:":[331],"capable":[338],"engaging":[340],"early":[346],"signs":[347],"activity":[349],"peripheral":[351],"immune":[352],"activation":[353],"largely":[356],"treatment-refractory,":[357],"non-immunogenic":[358],"population.":[360],"These":[361],"findings":[362],"support":[363],"additive":[365],"benefit":[366],"identify":[375],"biologically":[376],"regimens":[379],"subsequent":[383],"single":[384],"agent":[385],"development,":[386],"provide":[388],"further":[389],"combination":[392,406],"study.":[393],"Expansion":[394],"cohorts,":[395],"cutaneous":[397],"melanoma":[398],"PD-L1-positive":[400],"cancers,":[401],"planned,":[403],"pembrolizumab":[409],"initiated":[411],"(NCT04920383).":[412],"Clinical":[413],"trial":[414],"information:":[415],"NCT04186637.":[416]},"counts_by_year":[{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":1}],"updated_date":"2026-09-29T14:09:16.559479","created_date":"2022-06-13T00:00:00"}